The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
Ewa Anita JankowskaBridget-Anne KirwanMikhail Naum KosiborodJaved ButlerStefan D AnkerTheresa McDonaghMaria DorobantuJarosław DrożdżGerasimos S FilippatosAndre KerenIrakli KhintibidzeHans KragtenFelipe A MartinezMarco MetraDavor MilicicJose Carlos NicolauMarcus OhlssonAlexander ParkhomenkoDomingo Pascual FigalFrank RuschitzkaDavid SimHadi SkouriPeter van der MeerBasil S LewisJosep Comín ColetStephan von HaehlingAlain Cohen-SolalTabassome SimonWolfram DöhnerHenry J DargieMichael MotroTim FriedeVincent FabienFabio DorigottiStuart J PocockPiotr PonikowskiPublished in: European heart journal (2021)
In iron-deficient patients with HF and left ventricular ejection fraction ≤50% who had stabilized after an episode of acute HF, treatment with IV FCM, compared with placebo, results in clinically meaningful beneficial effects on HRQoL as early as 4 weeks after treatment initiation, lasting up to Week 24.
Keyphrases
- acute heart failure
- ejection fraction
- iron deficiency
- heart failure
- aortic stenosis
- left ventricular
- liver failure
- drug induced
- respiratory failure
- transcatheter aortic valve replacement
- high dose
- acute myocardial infarction
- cardiac resynchronization therapy
- aortic valve
- hypertrophic cardiomyopathy
- intensive care unit
- low dose
- combination therapy
- wild type
- randomized controlled trial
- aortic dissection
- clinical trial
- hepatitis b virus
- phase iii
- replacement therapy
- percutaneous coronary intervention